Sign In
Buy CAMP
$3.96
-0.230 (-5.49%)
At Close: Jun 15, 2026
Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave
07:00am, Tuesday, 16'th Jun 2026
Live demo listening session to approve artists onto the platform in real time New “golden ticket” subscriptions reward breakout performers on the spot Studio takeover and on-site activations give
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity
06:30am, Monday, 08'th Jun 2026
Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralization continuity and new high-grade targets for 2026 work.
Mercator Gold Exploration Priorities & Strategy
06:01am, Tuesday, 26'th May 2026
Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising historic work including high-grade intercepts of 5.6 metres of 4.87 g/t gold Vancouver, British Colum
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st May 2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline o
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
08:11pm, Thursday, 07'th May 2026
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.62 per share a year ago.
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
04:05pm, Thursday, 07'th May 2026
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGA
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
08:00am, Tuesday, 28'th Apr 2026
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscover
Canadian GoldCamps Announces Extension of Price Protection for Non-Brokered Private Placement
04:05pm, Tuesday, 21'st Apr 2026
Vancouver, British Columbia – TheNewswire - April 21, 2026 – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (the “ Company ”) announces that, in connection with its previously an
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 17'th Apr 2026
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline
Canadian GoldCamps Provides Corporate & Technical Work Program Updates
05:30pm, Tuesday, 14'th Apr 2026
Vancouver, April 14, 2026 – TheNewswire – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide a corporate update following the successful completion of its definitiv
CAMP4 Appoints Michael MacLean to its Board of Directors
07:00am, Tuesday, 24'th Mar 2026
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline
Canadian GoldCamps Announces Non-Brokered Private Placement of up to $2 Million
07:45pm, Friday, 06'th Mar 2026
Vancouver, British Columbia – March 6, 2026 – TheNewswire – Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (the “ Company ”) is pleased to announce a non-brokered private pla
CAMP4 to Participate in Upcoming Investor Conferences
04:05pm, Friday, 06'th Mar 2026
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
04:05pm, Thursday, 05'th Mar 2026
GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-
